Biopharma Titan Tim Walbert Joins Patient Square in Strategic PE Play

MENLO PARK, CA – May 06, 2026 – In a move that reverberates through the intersecting worlds of high finance and life sciences, Patient Square Capital has appointed Timothy P. Walbert as a Senior Advisor. Walbert, the celebrated former CEO of Horizon Therapeutics and a key architect of the blockbuster drug HUMIRA®, brings more than three decades of biopharmaceutical leadership to the prominent healthcare investment firm. The appointment is far more than a high-profile hire; it signals a deliberate and powerful strategic maneuver by Patient Square to deepen its operational expertise as it intensifies its focus on the fiercely competitive therapeutics sector.

Patient Square Capital, a firm managing over $18 billion in assets, has built its reputation on a partnership model that pairs capital with deep industry knowledge to foster growth in companies aiming to improve health outcomes. Walbert's arrival is a definitive statement of that strategy in action, equipping the firm with one of the industry's most proven leaders in scaling biopharma companies from clinical-stage entities to global commercial powerhouses.

A Strategic Play for Biopharma Dominance

The role of a Senior Advisor in private equity has evolved significantly from a ceremonial title to a critical, hands-on position. These industry veterans are the operational engines that help investment firms vet complex deals, drive post-acquisition value, and mentor the leadership of portfolio companies. Walbert’s appointment is the quintessential example of this modern paradigm.

“Tim is an extremely accomplished leader and business builder with a proven history of delivering impactful therapies to patients and creating significant long-term value,” said Jim Momtazee, Managing Partner of Patient Square Capital. “We have known Tim for a long time and believe that his depth of experience will be an exceptional resource to our team and our portfolio companies as we expand our investment activities in the therapeutics sector.”

This expansion is already well underway. Patient Square's portfolio includes a range of innovative companies that stand to benefit directly from Walbert's guidance. Firms like Kriya Therapeutics, which is developing gene therapies for complex diseases, and Apollo Therapeutics, with its diversified pipeline of over 20 programs, represent the exact type of high-science, high-potential investments where seasoned operational leadership can mean the difference between a scientific breakthrough and a commercial success. Furthermore, Patient Square’s creation of Enavate Sciences, a dedicated platform company designed to fund and support emerging therapeutic ventures, provides a perfect ecosystem for Walbert to apply his company-building acumen.

His experience is not just strategic but granular. Having led the global launch of HUMIRA® at Abbott—a drug that became one of the best-selling pharmaceuticals of all time—Walbert possesses an unparalleled understanding of commercialization, market access, and life-cycle management. This is precisely the kind of expertise that can help a development-stage company navigate the perilous journey from lab to patient.

The Walbert Effect: From CEO to Kingmaker

To understand the significance of Walbert's move to Patient Square is to understand his career trajectory. His legacy was cemented at Horizon Therapeutics, which he transformed from a small startup into a biopharmaceutical giant with nearly $4 billion in annual sales. The company's focus on rare and rheumatic diseases culminated in its staggering $28.3 billion acquisition by Amgen in 2023—one of the largest deals in the industry's recent history.

Rather than receding from the industry, Walbert has strategically pivoted from a singular operational role to a broader, more influential position as a senior statesman. His post-Horizon activities include serving as a Senior Advisor to Amgen, Managing Partner of HRZN Partners LLC, and holding numerous board seats at companies like BioMarin Pharmaceutical, Catalent, and Mirum Pharmaceuticals. He also serves as Chairman of the Board for Latigo Biotherapeutics, further demonstrating a commitment to nurturing the next generation of biopharma leaders.

His transition to Patient Square Capital is the logical next chapter in this evolution. It places him at the nexus of capital and innovation, where he can leverage his experience across an entire portfolio of companies, multiplying his impact. It is a shift from running one company to influencing many, effectively becoming a kingmaker in the sector he helped build.

“Patient Square Capital has built a highly differentiated platform and a strong record of partnering with management teams to create enduring value in health care,” Walbert commented on his appointment. “I’m pleased to join the firm as a Senior Advisor and look forward to contributing my experience in support of the team and its portfolio companies as they advance innovations that improve patient outcomes.”

The New Arms Race in Private Equity

Walbert’s recruitment is also a powerful illustration of a broader trend: the escalating “talent war” in private equity. As deal-making becomes more competitive and valuations remain high, investment firms are increasingly realizing that capital alone is not enough to guarantee returns. The new arms race is for operational expertise—the proven, real-world experience of industry titans who can drive genuine transformation within portfolio companies.

Firms like Blackstone, KKR, and Carlyle Group have been actively recruiting former CEOs and top executives for years, embedding them in their investment processes. This strategy is particularly crucial in healthcare, where scientific complexity, regulatory hurdles, and reimbursement challenges require specialized knowledge that a traditional finance professional may lack. By bringing Walbert into its fold, Patient Square is not just adding a name to its roster; it is acquiring a strategic asset that enhances its capabilities across the entire investment lifecycle.

This includes everything from deal sourcing, where Walbert's extensive network can unlock unique opportunities, to due diligence, where his operational eye can identify potential pitfalls and opportunities that others might miss. Most importantly, it impacts post-acquisition value creation, where he can provide direct, actionable guidance to help companies accelerate growth, optimize operations, and prepare for a successful exit.

For entrepreneurs and management teams of biopharma companies, the presence of someone like Walbert on an investment team makes a firm like Patient Square an exponentially more attractive partner. It signals a commitment not just to financial support, but to a genuine partnership built on shared experience and a deep understanding of what it takes to succeed in the demanding world of drug development. This fusion of capital and seasoned leadership is increasingly defining the future of healthcare investment, and Patient Square has just made a decisive move to solidify its position at the forefront of this evolution.